Twitxy Saved

Pierce

Verified account This account is verified. Learn more

@PierceOgdenJ

Co-Founder / CTO @manifoldbio. PhD Synthetic Biology in the Church Lab. I build multiplex measurement technologies to enable de novo protein design.
Earth Joined February 2013
1.3K Following 1.5K Followers 1K Posts

Latest posts 5

Pinned post

Pierce Verified account @PierceOgdenJ
Today, we’re announcing mBER-2, our latest AI protein design system, and sharing a bit of how we use it to explore biology in vivo at scale.

For a long time, we’ve been working on what I think of as “frontier problems” in medicine and biology. We know a lot about the targets involved in disease, but there is still an enormous amount of biology we haven’t explored, and potential uses for that biology we haven’t discovered.

One of those problems is drug delivery. There are thousands of potential targets, and most receptors remain unexplored as routes for delivering medicines. We want to understand which ones we can use, where they can take a drug, and what kinds of molecules make that possible.

Ultimately, we need to test these molecules in vivo to understand what they actually do. We’ve spent the last six years building measurement technologies that let us generate millions of measurements in living systems.

mBER-2 is an AI protein design system built for that scale of in vivo measurement. Our goal is to generate binders across the full range of targets we care about, while systematically exploring the possible binding sites on each one. It’s not just what you bind, but where and how you bind that determines whether a molecule performs it's function. mBER-2 lets us probe those differences at massive scale.

We’re also sharing a look at some of our in vivo data. We’ve designed more than 50 million molecules across over 4,000 targets, and screened millions of molecules in living systems. By probing hundreds of receptors, we’ve found new pathways for delivering genetic medicines into fat that outperform industry benchmarks by a large margin.

This is just the beginning. We call the space of all bindable sites across proteomes the EpiTome. As we explore it, we’re building the data to connect AI design, receptor binding, and what a molecule actually does in a living organism.

Much like the idea of a virtual cell, we envision a Virtual Organism that helps us design medicines with specific properties in mind. The foundation is our own in vivo data, connecting molecular design to outcomes measured in living systems.

The endgame is to use AI to explore more biology, measure what happens, and use what we learn to design better medicines. Every round should deepen our understanding of biology and improve our ability to build molecules that do what we need them to do.
16 replies 51 reposts 312 likes 48K views View on X
Pierce Verified account @PierceOgdenJ
One of the most exciting advances of mBER-2 is microbinders. These are tiny, structured peptides (just 10–45 amino acids long) that let us explore binding sites that larger formats like antibodies and VHHs can miss.

We started investigating these because of their potential for making different kinds of medicines, especially microbinder–siRNA conjugates. Hitting a different site on the same receptor can change what a molecule does in vivo, so having more ways to reach those sites is a big deal.

Their small size could also help with tissue penetration and make it easier to fit an effective dose into a small injection. Ultimately, we want to make medicines people can easily take at home instead of going in for infusions.

With mBER-2, we designed binders across 50 different microbinder formats and experimentally found specific binding hits in 31 of them. In some cases, microbinders produced hits where larger formats aimed at the same sites didn’t.

I think microbinders could help take peptide medicines from discovery to AI design: choosing the target and binding site we care about, designing peptides to match, and then testing what they actually do in vivo.

Read our blog and technical report for more info!
Pierce Verified account @PierceOgdenJ Sep 22
Today, we’re announcing mBER-2, our latest AI protein design system, and sharing a bit of how we use it to explore biology in vivo at scale.

For a long time, we’ve been working on what I think of as “frontier problems” in medicine and biology. We know a lot about the targets involved in disease, but there is still an enormous amount of biology we haven’t explored, and potential uses for that biology we haven’t discovered.

One of those problems is drug delivery. There are thousands of potential targets, and most receptors remain unexplored as routes for delivering medicines. We want to understand which ones we can use, where they can take a drug, and what kinds of molecules make that possible.

Ultimately, we need to test these molecules in vivo to understand what they actually do. We’ve spent the last six years building measurement technologies that let us generate millions of measurements in living systems.

mBER-2 is an AI protein design system built for that scale of in vivo measurement. Our goal is to generate binders across the full range of targets we care about, while systematically exploring the possible binding sites on each one. It’s not just what you bind, but where and how you bind that determines whether a molecule performs it's function. mBER-2 lets us probe those differences at massive scale.

We’re also sharing a look at some of our in vivo data. We’ve designed more than 50 million molecules across over 4,000 targets, and screened millions of molecules in living systems. By probing hundreds of receptors, we’ve found new pathways for delivering genetic medicines into fat that outperform industry benchmarks by a large margin.

This is just the beginning. We call the space of all bindable sites across proteomes the EpiTome. As we explore it, we’re building the data to connect AI design, receptor binding, and what a molecule actually does in a living organism.

Much like the idea of a virtual cell, we envision a Virtual Organism that helps us design medicines with specific properties in mind. The foundation is our own in vivo data, connecting molecular design to outcomes measured in living systems.

The endgame is to use AI to explore more biology, measure what happens, and use what we learn to design better medicines. Every round should deepen our understanding of biology and improve our ability to build molecules that do what we need them to do.
View quoted post on X
2 replies 10 reposts 85 likes 8.9K views View on X
Pierce Verified account @PierceOgdenJ
I've known @rohilbadkundri and @kalyanmpalepu for several years and they are among the most talented thinkers and cracked coders I have ever met. Congrats in the super exciting and novel work! I have yet to see others making as big and impact in the late stage of drug development prediction as these two.

Excited for what the future holds with them working on this huge problem with big impacts for humanity! This is a big step towards realizing the promise of AI to affect clinical development.
Rohil Badkundri @rohilbadkundri Mar 30
We used AI to predict the failure of a Phase 3 trial before the results were announced. Today, we're publishing 10 more predictions for the future.

Thread 🧵
View quoted post on X
Pierce Verified account @PierceOgdenJ
Really great collaboration between @ManifoldBio and @nvidia to test 1M de novo designed binders against 127 targets, measuring over 100 million potential protein-protein interactions! This was a great collaboration with some very exciting results. NVIDIA's new Proteina-Complexa method is SOTA for de novo minibinder design. If you're interested in designing minibinders to targets you couldn't hit with other methods, try it out!

I'm particularly excited about what this large scale data enables. As we generate 1000s of experimentally validated structures, this data becomes the input to training new protein design models. At Manifold, we are generating datasets of this size continuously, and have experimentally validated thousands of de novo designed binders across many formats (VHH, minibinders, peptides, etc). New models will open up new hard to hit targets, paired with our large scale in vivo measurement, will enable us to create previously impossible therapeutics.

Up next is training new models on this and other data we have generated, stay tuned! And thanks to NVIDIA for setting up such a great collaboration, its been fun and fruitful!
🧵 We ran the largest head-to-head benchmark of protein binder design methods in the wet lab.

Project page: research.nvidia.com/labs/genair/pr…

1 million designs. 127 targets. RFdiffusion, BindCraft, BoltzGen, and Proteina-Complexa — all tested side by side.👇
View quoted post on X
4 replies 37 reposts 155 likes 24K views View on X
Pierce Verified account @PierceOgdenJ
If you are interested in training foundation / reasoning models on massive corpus of novel in vivo and de novo protein design data, please get in touch. We have the largest corpus of in vivo data on molecules ever created, a huge opportunity for the right person!
Gleb Kuznetsov Verified account @glebkuz Mar 5
We're growing the AI team at @ManifoldBio, starting with a role to train protein foundation models on our proprietary data.

I believe Manifold is the most interesting place to work on protein design. We're designing and testing millions of binders per month, including in vivo, and accelerating. No one else has data like this.

If you have deep experience pretraining or fine-tuning protein models and want to work somewhere the data actually lets you push beyond what public datasets can enable, please reach out.
View quoted post on X